Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype.

BACKGROUND Multiple endocrine neoplasia type 1 (MEN1) is an autosomal-dominant hereditary disorder associated with the development of endocrine tumors due to reduced expression of the tumor suppressor protein menin. Recent studies indicate a general role of menin in carcinogenesis, affecting the prevalence and clinical course of common non-endocrine tumors such as breast cancer, hepatocellular carcinoma and melanoma. Here we report a new germline missense mutation of Men1 in a German family with atypical tumor phenotype over three generations. Based on the type of mutation, we discuss possible changes in menin function leading to atypical tumorigenesis and present the clinical significance of such findings. CASE PRESENTATION A German family with a history of primary hyperparathyroidism presented to our Hospital for further evaluation. Members of the family demonstrated many different atypical tumors, such as renal cell carcinoma, papillary thyroid cancer and prostate cancer. DNA sequencing from peripheral blood revealed a novel mutation: Ser38Cys [TCC>TGC] in exon 2, codon 38 of Men1. This novel mutation is located in a region of menin which is responsible for interactions with the transcription factor JunD. This factor has recently been associated with prostate cancer. DNA sequencing of two of the atypical tumors (prostate cancer, papillary thyroid cancer) did not reveal a loss of heterozygosity, indicating an impact on menin expression and function in the heterozygous state, in line with results in +/-Men1 mutant mice developing prostate cancer. CONCLUSION The results and clinical course of disease in this case indicate the potential role of menin in the development of non-endocrine or atypical-endocrine tumors in MEN1 patients. Further investigations are needed to clarify both the general role of menin and the importance of specific mutations in carcinogenesis. Nevertheless, in families with uncommon manifestations of the syndrome early diagnostic adjustments should be considered.

[1]  G. Valk,et al.  Reply to: Breast cancer risk in MEN1 – a cancer genetics perspective , 2015, Clinical endocrinology.

[2]  P. Brennan Breast cancer risk in MEN1 – a cancer genetics perspective , 2015, Clinical endocrinology.

[3]  S. O'meara,et al.  Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing , 2015, Journal of Clinical Pathology.

[4]  Z. Yin,et al.  The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma. , 2014, Journal of hepatology.

[5]  V. Fendrich,et al.  Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. , 2014, The Journal of clinical endocrinology and metabolism.

[6]  G. Valk,et al.  Breast-cancer predisposition in multiple endocrine neoplasia type 1. , 2014, The New England journal of medicine.

[7]  Yao Yang,et al.  RETRACTED ARTICLE: MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN , 2014, Tumor Biology.

[8]  G. Wilding,et al.  Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression , 2014, The Prostate.

[9]  M. Brandi,et al.  Sarcomatoid carcinoma of the kidney in a MEN1 patient: case report and genetic profile. , 2014, Endocrine journal.

[10]  P. Chanson,et al.  Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study. , 2013, Human molecular genetics.

[11]  Michael R. Green,et al.  MEN1 Is a Melanoma Tumor Suppressor That Preserves Genomic Integrity by Stimulating Transcription of Genes That Promote Homologous Recombination-Directed DNA Repair , 2013, Molecular and Cellular Biology.

[12]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[13]  Qi Zhao,et al.  Expression and subcellular localization of menin in human cancer cells. , 2012, Experimental and therapeutic medicine.

[14]  Zijie Feng,et al.  Menin represses malignant phenotypes of melanoma through regulating multiple pathways , 2011, Journal of cellular and molecular medicine.

[15]  Zhao-Qi Wang,et al.  Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice , 2010, BMC Cancer.

[16]  B. Harding,et al.  Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia , 2009, Endocrine-related cancer.

[17]  G. Valk,et al.  Multiple Endocrine Neoplasia Type 1 (MEN 1) , 2009 .

[18]  J. Cobb,et al.  Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome , 2005, Molecular Cancer.

[19]  G. Chrousos,et al.  The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  R. Weigel,et al.  Genetic Analysis of a Papillary Thyroid Carcinoma in a Patient with MEN1 , 2001, Annals of Surgical Oncology.

[21]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.